Drug Topics
OCTOBER 5, 2023
Collaboration among faculty, students, national associations, and community pharmacy leaders is crucial as pharmacy practice continues to transform.
Pharmacy Is Right For Me
OCTOBER 5, 2023
The CVS Health Minority Scholarship for Pharmacy Students was awarded to five outstanding underrepresented minority (URM) student pharmacists who are currently pursuing their PharmD degree. Selected awardees demonstrated outstanding leadership, academic success, and a commitment to advancing the profession of pharmacy and patient care. This scholarship will support them in their goal of becoming pharmacists by reducing financial barriers.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
OCTOBER 5, 2023
It’s crucial to be openminded about these approaches, and to convey accurate information to patients in a nonjudgmental manner.
Pharmacy Times
OCTOBER 5, 2023
Study findings indicated that many health care facilities are recovering from the COVID-19 pandemic and shortage of staff, which has caused door-to-balloon times to lag.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
OCTOBER 5, 2023
The Food and Drug Administration’s expert vaccine advisory panel on Thursday unanimously endorsed the idea of taking a strain of influenza viruses that no longer appears to circulate out of flu shots as quickly as possible, pressing the FDA and manufacturers to try to get the work done on an expedited timeline. While a representative of vaccine manufacturers warned it may not be possible to remove the influenza B/Yamagata component from the flu vaccines that will be made for the Northern
Pharmacy Times
OCTOBER 5, 2023
Study shows a a significant burden of hospitalizations associated with respiratory syncytial virus during the 2021-2022 season compared with the prepandemic period.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
OCTOBER 5, 2023
Tune in to this episode of Public Health Matters to gain a profound understanding of health equity, the enduring racial disparities in health care, and the essential work of supporting individuals as they reenter society.
Pharmaceutical Commerce
OCTOBER 5, 2023
In an interview at LogiPharma USA 2023 with Pharma Commerce Editor Nicholas Saraceno, Tracy Nasarenko, Sr. Director of Community Engagement for Pharmaceuticals, GS1 US highlights her “DSCSA—Final Checks to Have Before Deadlines.
Pharmacy Times
OCTOBER 5, 2023
Investigators found that the adjusted mean change in A1C was –0.62% for dapagliflozin compared to 0.41% for a placebo in patients with type 2 diabetes.
STAT
OCTOBER 5, 2023
SAN DIEGO — It was spring 2020, and Histogen, a small biotech with big ambitions to regenerate tissues throughout the body and turn a profit in the process, had just gone public. The company’s leadership believed they were poised for success — until everything slowly and irreversibly fell apart. Three years later, Histogen no longer develops therapies.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
OCTOBER 5, 2023
Naveen Mansukhani, BPharm, National Operations Director for Cardinal Health Retail Pharmacy Services, discussed how he is celebrating American Pharmacists Month.
Fierce Pharma
OCTOBER 5, 2023
Merck’s Keytruda is riding a winning streak in bladder cancer. | Merck’s Keytruda is riding a winning streak in bladder cancer. Following FDA approvals in the metastatic and non-muscle invasive settings, the anti-PD-1 therapy has delivered a positive readout in muscle-invasive urothelial carcinoma.
Fierce Healthcare
OCTOBER 5, 2023
Healthcare providers have promised that timely, convenient and affordable care built with the patient in mind is just around the corner. | Retailers are placing big bets on their customers’ willingness to trust them with their healthcare needs. Consumer trust in our healthcare system is at an all-time low, largely due to stubborn barriers like the lack of price transparency and equal access to care.
Fierce Pharma
OCTOBER 5, 2023
Mirati Therapeutics enjoyed a stock-price spike Thursday after rumors started swirling about a potential buyout by French drug giant Sanofi. | Mirati Therapeutics saw its stock price spike Thursday at the possibility of a buyout from Sanofi. The French pharma has been evaluating a potential acquisition of the KRAS drug developer, Bloomberg reports, citing unnamed sources.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
STAT
OCTOBER 5, 2023
STAT’s Mohana Ravindranath and Annalisa Merelli will be at HLTH in Las Vegas and will be writing a daily email dispatch from the meeting. Sign up here to get it. Health leaders are jetting to Las Vegas this weekend for a meeting they say is crucial for clinching new deals and cooking up new startups — all while mingling with TV personalities, social media influencers, musicians and ten thousand other health care professionals on the industry’s flashiest exhibitor floor.
Fierce Pharma
OCTOBER 5, 2023
In Viatris' attempt to become the first company to reach the market with generic versions of Novo Nordisk’s diabetes and obesity juggernauts Ozempic and Wegovy, the company received good and bad ne | After hearing a petition from Viatris, the U.S. Patent and Trademark Office will conduct a review to determine the validity of a patent held by Novo Nordisk.
STAT
OCTOBER 5, 2023
The shortage of cancer drugs is not going away, but it may be easing slightly, a new national survey suggests. Based on questions posed to 29 of its 33 member hospitals, the National Comprehensive Cancer Network said Thursday that 86% of those cancer centers are experiencing a shortage of at least one type of generic chemotherapy drug, down from 90% in May.
Fierce Healthcare
OCTOBER 5, 2023
UnitedHealthcare's Surest, which axes deductibles and provides upfront pricing data to members, is the fastest growing product among its commercial plan lineup. | UnitedHealthcare's Surest, which axes deductibles and provides upfront pricing data to members, is the fastest growing product among its commercial plan lineup. And a new analysis offers a look as to why.
Fierce Pharma
OCTOBER 5, 2023
The abrupt departure of Lonza’s CEO last month clearly hasn’t dampened the Swiss CDMO’s dealmaking prowess. | Lonza has extended a long-term collaboration with an unnamed “major global biopharmaceutical partner” to crank up commercial supply of antibody-drug conjugates at its site in Visp, Switzerland. The deal is set to boost Lonza’s current bioconjugation capacity fourfold, thanks to the addition of two new bioconjugation suites.
Fierce Healthcare
OCTOBER 5, 2023
Some 42% of Native Americans have visited the ER because of a Type 2 diabetes complication, a new survey showed. | Some 42% of Native Americans have visited the ER because of a Type 2 diabetes complication, according to the survey.
Hospital Pharmacy Europe
OCTOBER 5, 2023
The first pilot cohort of pharmacists have completed the Royal Pharmaceutical Society (RPS) advanced e-portfolio pathway, which was launched in March 2023 to recognise and quality assure advanced pharmacist practice in England. The seven pharmacists are now eligible for the NHS England (NHSE) Centre of Advancing Practice’s ‘Advanced’ digital badge, and those who are members of the RPS may now use the membership affix MRPharmS (Advanced).
Drug Topics
OCTOBER 5, 2023
Fezolinetant (Veozah) is approved for the treatment of moderate to severe vasomotor symptoms (ie, hot flashes and night sweats) related to menopause.
STAT
OCTOBER 5, 2023
LONDON — The Japanese firm Kyowa Kirin is acquiring gene therapy maker Orchard Therapeutics in a $400 million deal, the companies said Thursday. Kyowa Kirin is paying $16 per share — a nearly 100% premium on Orchard’s Wednesday closing price — in cash, amounting to roughly $390 million. Orchard shareholders stand to earn another $90 million if Orchard’s gene therapy, Libmeldy, wins U.S. approval.
Fierce Healthcare
OCTOBER 5, 2023
Froedtert Health is buying out Ascension’s 50% stake in a Wisconsin health plan jointly run by the nonprofit health systems, the former announced this week. | The deal, which is pending review, would give Froedtert Health full ownership of a commercial and Medicare payer with 117,000 members.
Fierce Pharma
OCTOBER 5, 2023
Takeda will withdraw lung cancer drug Exkivity after a confirmatory trial failure. Kyowa Kirin is buying gene therapy biotech Orchard Therapeutics. | Takeda will withdraw lung cancer drug Exkivity after a confirmatory trial failure. Kyowa Kirin is buying gene therapy biotech Orchard Therapeutics. Biogen's biosimilar version of Roche's Actemra, bought from Bio-Thera Solutions, won an FDA nod.
STAT
OCTOBER 5, 2023
Will we ever get an HIV vaccine? And is the oft-criticized institution that awards the Nobel Prize each year showing signs of evolution? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. It’s Nobel week on the podcast, and reporter Megan Molteni details the unique story of this year’s winners for medicine, Katalin Karikó and Drew Weissman.
Fierce Pharma
OCTOBER 5, 2023
Five weeks removed from slashing 25% of its workforce amid problems wi | Five weeks removed from slashing 25% of its workforce amid problems with its groundbreaking geographic atrophy drug, Apellis is making progress in re-accelerating the launch of Syfovre. Ahead of its quarterly earnings presentation, Apellis estimated sales of approximately $74 million for the third quarter for Syfovre and a rekindling of demand in recent weeks as doctors get a better handle on the risk of vascular retinitis.
STAT
OCTOBER 5, 2023
It should be obvious that medical school and clinical experience, in themselves, can’t fully prepare someone for the C-suite, any more than an MBA and corporate leadership experience equip someone to be a doctor. But all too many health care organizations promote their best physicians to chief medical officer (CMO) on the assumption that they can pick up the new skills they need on the fly.
Fierce Pharma
OCTOBER 5, 2023
Judgment Day has come for Amgen’s first-in-class KRAS inhibitor Lumakras as the FDA’s Oncologic Drugs Advisory Committee (ODAC) gathered Thursday to weigh the merits of the cancer med’s phase 3 cli | Judgment Day has come for Amgen’s first-in-class KRAS inhibitor Lumakras as the FDA’s Oncologic Drugs Advisory Committee gathered Thursday to weigh the merits of the cancer med’s phase 3 clinical trial CodeBreak 200.
Pharmacy Times
OCTOBER 5, 2023
Little progress has been made in developing treatments that can help to stop Ewing sarcomas from spreading or coming back.
Drug Store News
OCTOBER 5, 2023
The retailer’s common stock will continue to be listed and traded on the NYSE during the 'cure periods,' subject to the company’s compliance with other continued listing requirements.
Pharmacy Times
OCTOBER 5, 2023
Patients often turn to dietary supplements for the management of osteoarthritis, one of which is turmeric.
STAT
OCTOBER 5, 2023
The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday. Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS , which is one of the most common genetic mutations in cancer.
European Pharmaceutical Review
OCTOBER 5, 2023
Maja Pedersen has been appointed as Chief Quality Officer (CQO), to lead FUJIFILM Diosynth Biotechnologies’ global quality team. Pedersen’s new role is effective immediately. As a member of the executive leadership team, she will report to President and CEO Lars Petersen, who was appointed in June this year. With 20 years of leadership experience in the life sciences and biopharma sector, Pedersen has previously had senior leadership positions in quality assurance (QA) and quality control ( QC )
Expert insights. Personalized for you.
200 
Let's personalize your content